Literature DB >> 19557469

[Systemic chemotherapy for bladder cancer: news in 2009].

M Retz1, J E Gschwend, J Lehmann.   

Abstract

This review summarizes the results of first-line and second-line systemic chemotherapy for advanced urothelial carcinoma as well as data from adjuvant and neoadjuvant trials for locally advanced bladder cancer. Whereas conventional systemic chemotherapy prevailed for over two decades, targeted therapeutics have been introduced to treat urothelial cancer during recent years. As in other tumor entities, molecular profiling will presumably emerge in the future as a means to tailor individual therapy.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19557469     DOI： 10.1007/s00120-009-2021-5

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


  27 in total

1.  Sorafenib in advanced clear-cell renal-cell carcinoma.

Authors:  Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

2.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

3.  Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study.

Authors:  Ulka N Vaishampayan; James R Faulkner; Eric J Small; Bruce G Redman; Wayne L Keiser; Daniel P Petrylak; E David Crawford
Journal:  Cancer       Date:  2005-10-15       Impact factor: 6.860

4.  Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration.

Authors: 
Journal:  Eur Urol       Date:  2005-04-25       Impact factor: 20.096

5.  Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95).

Authors:  Jan Lehmann; Margitta Retz; Christina Wiemers; Joachim Beck; Joachim Thüroff; Christoph Weining; Peter Albers; Detlef Frohneberg; Tanja Becker; Peter-Jörg Funke; Peter Walz; Sigrun Langbein; Frank Reiher; Matthias Schiller; Kurt Miller; Stephan Roth; Tilman Kälble; Donald Sternberg; Stefan Wellek; Michael Stöckle
Journal:  J Clin Oncol       Date:  2005-06-06       Impact factor: 44.544

6.  Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study.

Authors:  S Krege; V Rembrink; C Börgermann; T Otto; H Rübben
Journal:  J Urol       Date:  2001-01       Impact factor: 7.450

7.  Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.

Authors:  Peter Albers; Roswitha Siener; Susanne Krege; Hans-Uwe Schmelz; Klaus-Peter Dieckmann; Axel Heidenreich; Peter Kwasny; Maik Pechoel; Jan Lehmann; Sabine Kliesch; Kai-Uwe Köhrmann; Rolf Fimmers; Lothar Weissbach; Volker Loy; Christian Wittekind; Michael Hartmann
Journal:  J Clin Oncol       Date:  2008-05-05       Impact factor: 44.544

Review 8.  Clinical activity of vinflunine in transitional cell carcinoma of the urothelium and other solid tumors.

Authors:  Joaquim Bellmunt; Francois-Michel Delgado; Claude George
Journal:  Semin Oncol       Date:  2008-06       Impact factor: 4.929

9.  Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis.

Authors:  Fabrice Andre; Kristine Broglio; Henri Roche; Miguel Martin; John R Mackey; Frederique Penault-Llorca; Gabriel N Hortobagyi; Lajos Pusztai
Journal:  J Clin Oncol       Date:  2008-06-01       Impact factor: 44.544

10.  Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer.

Authors:  J Bellmunt; J Cos; R Clèries; M Pérez; A Ribas; N Eres; J E Murio; C Margarit; J Baselga
Journal:  Cancer Invest       Date:  2002       Impact factor: 2.176
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.